Form 4: Avalo Therapeutics Director Rita Jain Granted 40,200 Stock Options

Avalo Therapeutics, Inc. Director Rita Jain was granted 40,200 stock options with an exercise price of $4.47, vesting over three years.

Summary

• Rita Jain, a Director of Avalo Therapeutics, Inc. (AVTX), was granted 40,200 stock options.
• The stock options have an exercise price of $4.47 per share.
• The options vest in three substantially equal installments on the first, second, and third anniversaries of the grant date, which was June 17, 2025.
• Vesting is contingent upon Ms. Jain's continued service on each respective vesting date.
• The stock options have an expiration date of June 17, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (stock option grant) which is generally a neutral event, but the grant itself can be seen as a positive for aligning director interests with shareholder value.

Positives

• The grant of 40,200 stock options to Director Rita Jain aligns her financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period, providing a significant timeframe for the director to benefit from potential stock price appreciation.

Future Outlook

The stock options granted are designed to incentivize the director's continued service and align her interests with the company's long-term performance, with vesting scheduled over three years.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, aiming to align the interests of board members with long-term shareholder value creation. This type of equity compensation is a standard component of director remuneration packages across publicly traded companies.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation, consistent with practices observed in many publicly traded companies, particularly within the biotechnology sector, to incentivize long-term commitment and performance.

Related Party Transactions

• Grant of 40,200 stock options to Rita Jain, a Director of Avalo Therapeutics, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: Potential long-term alignment of the director's interests with shareholder value through equity incentives.

Next Steps

• The stock options will vest in three substantially equal installments on the first, second, and third anniversaries of the grant date (June 17, 2025), subject to continued service.

Key Dates

Keywords

Avalo Therapeutics, AVTX, stock options, director compensation, insider transaction, equity grant, Form 4